Biotech | 03 September 2021
DGCI green lights Biological E for Phase 2/3 trials of its Covid-19 vaccine candidate for children
The trial will be conducted across 10 sites in India
The trial will be conducted across 10 sites in India
This is Omeza’s first Rx product and the first drug/device combination matrix of its kind for chronic wound care
The vaccine is designed to neutralise the virus in the nostril itself and prevent it from penetrating deep down into the respiratory tract
The drug is also intended for the treatment of glioblastoma multiforme
Results reinforce the well-established safety profile of Dupixent - the first-ever biologic medicine for atopic dermatitis currently approved for patients as young 6 years old
The value of the contract is estimated to be between Rs 20-30 crores per year for the next three years
It is estimated that over 11,000 children across Europe, Middle East, and Africa are affected by achondroplasia and could be eligible for treatment with Voxzogo
The centre established by Nucleome Informatics will take up the sequencing of 5,000 Covid genomes and 500 human genomes in the coming months
The manufacture of finished doses will commence in 2022 and at full operational capacity, the annual production is expected to exceed 100 million doses annually
First results demonstrate favourable tolerability of TQL-1055 at all dose levels
The co-investment of CHF 4 million will result in capacity expansion and support the market introduction of the customer's lead compound
Trillium’s portfolio includes biologics that are designed to enhance the ability of patients’ innate immune system to detect and destroy cancer cells
Viraleze was developed for application in the nasal cavity to help reduce exposure to respiratory viruses, including SARS-CoV-2. The product is registered for sale in Europe and India, and available online in certain markets
CDSCO gives the green signal as HGCO19 was safe, tolerable and immunogenic in the participants of the study
When the Delfi technology was used as a pre-screen to determine if a low dose CT (LDCT), should be performed, the combined approach led to the detection of 90% of lung cancers, including 80% of stage I cancers
XELJANZ is the first and only Janus kinase (JAK) inhibitor approved in Europe for the treatment of polyarticular JIA and juvenile PsA and has received regulatory approval in four indications in the European Union, the most of any JAK inhibitor
The software enables real-time communication between patients, caregivers, physicians, and pharmacists and each cartridge in the device has a unique, traceable serial number registered to the patient
It is the only biopharmaceutical company in India to offer all three dosage strengths of the drug (125mcg, 250mcg, and 500mcg)
Preliminary data from the first 20 participants in Azerbaijan show antibodies to the SARS-CoV-2 virus spike protein (S-protein) elicited in 100% of cases
This is the world’s first Covid=19 DNA vaccine developed in partnership with DBT-BIRAC
Subscribe To Our Newsletter & Stay Updated
